New Delhi, November 12, 2025: Global pharma major Novo Nordisk has announced a price reduction of up to 37% for its obesity drug Wegovy in India, aiming to improve access to advanced weight-loss therapy amid surging demand across urban markets.
The move aligns with the government’s focus on affordable healthcare and preventive care, as obesity rates continue to climb in India. Analysts say this strategic cut could significantly increase prescriptions and patient adoption, especially in metros where weight management drugs are seeing strong interest.
Rising Demand for Weight-Loss Drugs in India
According to market research reports, India’s GLP-1 receptor agonist segment, which includes drugs for obesity and diabetes, is projected to grow at a CAGR of over 34% from 2025 to 2030. The country’s anti-obesity drug market, currently valued at around ₹3,000 crore, is expected to touch ₹25,000 crore by 2030.
A health survey shows nearly 29% of India’s adult population is classified as obese or overweight — translating to more than 250 million people. The accessibility of effective therapies like Wegovy could play a major role in tackling this growing public health concern.
Industry Impact and Market Outlook
Wegovy, based on semaglutide, is part of a global class of GLP-1 medications that have gained immense popularity for weight management. With India now offering more competitive pricing, experts believe Novo Nordisk has positioned itself to capture a leading share of the country’s weight-loss segment.
The price cut is also expected to spark competitive responses from other drugmakers such as Eli Lilly, which plans to introduce similar GLP-1-based treatments in India soon. Analysts forecast that this could reshape India’s obesity care landscape, moving it toward more medically supervised treatments rather than short-term solutions.
The Road Ahead
The lower price point could encourage corporate wellness programs, insurers, and clinics to integrate Wegovy into their offerings, making it easier for patients to access proven medical interventions for obesity.
For Novo Nordisk, India remains a key growth market in Asia, and the pricing revision reflects a long-term strategy to balance affordability with accessibility — a critical factor as obesity becomes one of India’s top lifestyle diseases.
